Peter Esser1, Katharina Kuba2, Angela Scherwath3, Lena Schirmer3, Frank Schulz-Kindermann3, Andreas Dinkel4, Friedrich Balck5, Uwe Koch3, Nicolaus Kröger6, Heide Götze2, Anja Mehnert2,3. 1. Department of Medical Psychology and Medical Sociology, University Medical Center Leipzig, Philipp-Rosenthal-Straße 55, 04103, Leipzig, Germany. peter.esser@medizin.uni-leipzig.de. 2. Department of Medical Psychology and Medical Sociology, University Medical Center Leipzig, Philipp-Rosenthal-Straße 55, 04103, Leipzig, Germany. 3. Department and Outpatient Clinic of Medical Psychology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20251, Hamburg, Germany. 4. Department of Psychosomatic Medicine and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Straße 22, 81675, Munich, Germany. 5. Department of Medical Psychology and Medical Sociology, University Hospital Carl Gustav Carus, Technical University of Dresden, Fetscherstraße 74, 01307, Dresden, Germany. 6. Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20251, Hamburg, Germany.
Abstract
PURPOSE: Despite the life-threatening character of allogeneic hematopoietic stem cell transplantation (allogeneic HSCT), very few longitudinal research exists on posttraumatic stress disorder (PTSD) symptomatology in this patient group. We investigated prevalence, temporal course and predictors of PTSD symptomatology in this population. METHODS: Patients were assessed before conditioning (T0), 100 days (T1), and 12 months after HSCT (T2). PTSD symptomatology was measured with the PTSD Checklist-Civilian Version. We conducted multilevel modeling and multiple regression analyses. RESULTS: Two hundred thirty-nine patients participated at baseline, 150 at T1, and 102 at T2. Up to 15 % met the criteria for PTSD at least once during the course of assessment. Fifty-two percent showed diagnostic relevant levels of intrusion, 30 % of avoidance, and 33 % of arousal at least once. Apart from arousal, which increased between T0 and T1 (γ = 0.56, p = 0.03), no other severity score significantly differed between time points. Being impaired by pain (γ = 2.89, p < 0.01), pain level (γ = 0.63, p = 0.02), and being female (γ = 3.81, p < 0.01) emerged as significant predictors of PTSD symptomatology when taking into account all time points. Acute plus chronic graft-versus-host-disease and longer hospital stay predicted PTSD symptomatology at T2 (γ = 3.39, p = 0.04; γ = 0.1, p = 0.03). CONCLUSIONS: A considerable number of patients undergoing allogeneic HSCT met the criteria for PTSD. PTSD symptomatology is prominent at all assessment points. Burden of pain, being female, and medical complications are risk factors for elevated levels of PTSD symptomatology. IMPLICATIONS FOR CANCER SURVIVORS: Psychological support should be offered not only after treatment but also in the long-term and even before HSCT. Professionals should be aware of the psychological consequences accompanied by pain and complications.
PURPOSE: Despite the life-threatening character of allogeneic hematopoietic stem cell transplantation (allogeneic HSCT), very few longitudinal research exists on posttraumatic stress disorder (PTSD) symptomatology in this patient group. We investigated prevalence, temporal course and predictors of PTSD symptomatology in this population. METHODS:Patients were assessed before conditioning (T0), 100 days (T1), and 12 months after HSCT (T2). PTSD symptomatology was measured with the PTSD Checklist-Civilian Version. We conducted multilevel modeling and multiple regression analyses. RESULTS: Two hundred thirty-nine patients participated at baseline, 150 at T1, and 102 at T2. Up to 15 % met the criteria for PTSD at least once during the course of assessment. Fifty-two percent showed diagnostic relevant levels of intrusion, 30 % of avoidance, and 33 % of arousal at least once. Apart from arousal, which increased between T0 and T1 (γ = 0.56, p = 0.03), no other severity score significantly differed between time points. Being impaired by pain (γ = 2.89, p < 0.01), pain level (γ = 0.63, p = 0.02), and being female (γ = 3.81, p < 0.01) emerged as significant predictors of PTSD symptomatology when taking into account all time points. Acute plus chronic graft-versus-host-disease and longer hospital stay predicted PTSD symptomatology at T2 (γ = 3.39, p = 0.04; γ = 0.1, p = 0.03). CONCLUSIONS: A considerable number of patients undergoing allogeneic HSCT met the criteria for PTSD. PTSD symptomatology is prominent at all assessment points. Burden of pain, being female, and medical complications are risk factors for elevated levels of PTSD symptomatology. IMPLICATIONS FOR CANCER SURVIVORS: Psychological support should be offered not only after treatment but also in the long-term and even before HSCT. Professionals should be aware of the psychological consequences accompanied by pain and complications.
Authors: S Kurosawa; T Yamaguchi; T Mori; H Kanamori; Y Onishi; N Emi; S Fujisawa; A Kohno; C Nakaseko; B Saito; T Kondo; M Hino; Y Nawa; S Kato; A Hashimoto; T Fukuda Journal: Bone Marrow Transplant Date: 2015-06-15 Impact factor: 5.483
Authors: M Díez-Campelo; J A Pérez-Simón; J R González-Porras; J M García-Cecilia; M Salinero; M D Caballero; M C Cañizo; E M Ocio; J F San Miguel Journal: Bone Marrow Transplant Date: 2004-10 Impact factor: 5.483
Authors: Jessica Liang; Stephanie J Lee; Barry E Storer; Bronwen E Shaw; Eric J Chow; Mary E Flowers; Elizabeth F Krakow; Merav Bar; Karen L Syrjala; Rachel B Salit; Chareeni E Kurukulasuriya; Heather S L Jim Journal: Biol Blood Marrow Transplant Date: 2018-08-09 Impact factor: 5.742
Authors: Steffen T Simon; Anne Pralong; Michael Hallek; Christoph Scheid; Udo Holtick; Marco Herling Journal: Ann Hematol Date: 2021-05-06 Impact factor: 3.673